Table 2.

HIV genotypic drug resistance mutations and predicted phenotypic drug resistance among newly diagnosed ART-naive HIV-infected adults in Taizhou, 2008–2011

Sample ID*	Subtype	Gender	Age (yr)	CD4	Drug resistance mutations					Level of drug resistance
					PI major	PI minor	NRTI	NNRTI	Other	Potential	Low	Intermediate	High
1	01AE	Female	21	459	M46I					ATV/r, FPV/r, IDV/r, LPV/r	NFV
2	01AE	Male	48	320	M46I					ATV/r, FPV/r, IDV/r, LPV/r	NFV
3	01AE	Male	59	275			M184 V			DDI	ABC		3TC, FTC
4	01AE	Male	24	290			T215S			ABC, DDI	AZT, D4 T
5	07BC	Male	62	551	V82A	A71 V				FPV/r, SQV/r	ATV/r, LPV/r	IDV/r, NFV
6	07BC	Female	48	10					E138G	ETR	RPV
7	08BC	Female	37	242			A62 V, T69N			AZT, D4 T	DDI
8	08BC	Female	36	410			A62 V, T69N			AZT, D4 T	DDI
9	08BC	Male	46	231			A62 V, T69N			AZT, D4 T	DDI
10	B	Male	27	449	L90M	L10I, A71 T	T215S	Y188L		LPV/r, ABC, DDI, ETR	FPV/r, IDV/r, AZT, D4 T	ATV/r, SQV/r	NFV, EFV, NVP, RPV
11	B	Male	24	437		A71 T	T215S			ABC, DDI	AZT, D4 T
12	B	Female	38	426				K103N, G190A		ETR, RPV			EFV, NVP
13	01AE	Male	73	317		L10F				FPV/r, NFV
14	01AE	Male	42	367		L10F				FPV/r, NFV
15	01AE	Female	39	278		L33F		V179E		FPV/r ,EFV, NVP
16	01AE	Male	35	428		L33F				FPV/r
17	01AE	Female	24	730				V108I		NVP
18	01AE	Male	45	330				V179D		EFV, ETR ,NVP, RPV
19	01AE	Male	25	379				V179D		EFV, ETR, NVP, RPV
20	01AE	Female	22	356				V179E		EFV, NVP
21	01AE	Male	50	318				V179E		EFV, NVP
22	01AE	Male	27	186				V179E		EFV, NVP
23	01AE	Male	25	301				V179E		EFV, NVP
24	01AE	Male	42	175				V179E		EFV, NVP
25	07BC	Female	26	317		L10I, A71 T				NFV
26	08BC	Male	40	233		A71 T	T69N	V179D		DDI, EFV, ETR, NVP, RPV
27	08BC	Male	44	552			T69S	V179D		EFV, ETR, NVP, RPV
28	08BC	Male	34	182			T69S	V179E		EFV, NVP
29	08BC	Female	30	90				V179D		EFV, ETR, NVP, RPV
30	08BC	Male	40	31				V179D		EFV, ETR, NVP, RPV
31	B	Male	44	470		A71 T		V179D		EFV, ETR, NVP, RPV
32	B	Female	53	119		L10I, A71 T				NFV
33	B	Male	40	237				V179D		EFV, ETR, NVP, RPV
34	B	Male	38	380				V179E		EFV, NVP
35	C	Female	22	874				V108I		NVP
36	C	Female	29	595				V108I		NVP
37	C	Female	23	513				V108I		NVP
38	C	Male	27	650				V108I		NVP

PIs, Protease inhibitors (ATV/r, atazanavir/r; FPV/r, fosamprenavir/r; IDV/r, indinavir/r; SQV/r, saquinavir/r; LPV/r, lopinavir/r); NRTIs, nucleoside reverse transcriptase inhibitors (DDI, didanosine; ABC, abacavir; 3TC, lamivudine; FTC, emtricitabine; AZT, zidovudine; D4 T, stavudine; TDF, tenofovir; NFV, nelfinavir); NNRTIs, non-nucleoside reverse transcriptase inhibitors (EFV, efavirenz; NVP, nevirapine; ETR, etravirine; RPV, rilpivirine).

^*Samples nos. 1–12 were determined to have low to high level of phenotypic drug resistance, i.e. HIVDR.